John Thomas Burns - 10 Jan 2025 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jan 2025, 17:34:56 UTC
Prior SEC filing
05 Dec 2024
Next SEC filing
05 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kostantinos Skordalos, Power of Attorney For: John Burns

Key filing fact

John Thomas Burns filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 14 Jan 2025.

Key facts

  • This page summarizes John Thomas Burns's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Jan 2025, 17:34.

Change

  • Previous filing in this sequence was filed on 05 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLS transaction

Common Stock

Award

Transaction value
$0
Shares
+113,000
Change %
+108%
Price
$0.000000
Shares after
217,762
Date
10 Jan 2025
Ownership
Direct
Footnotes
F1
SLS transaction

Common Stock

Award

Transaction value
$0
Shares
+81,300
Change %
+37%
Price
$0.000000
Shares after
299,062
Date
10 Jan 2025
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+169,500
Change %
Price
$0.000000
Shares after
169,500
Date
10 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
169,500
Exercise price
$0.9525
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person received an award of 113,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

Footnote F2

The Reporting Person received an award of 81,300 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

Footnote F3

One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .